Responses
Ovarian cancer
2022-RA-1267-ESGO A randomised clinical Trial Investigating olaparib, durvalumab and an anticancer vaccine, UV1 as maintenance therapy in patients with recurrent ovarian cancer. ENGOT-OV56-NSGO-CTU-DOVACC
Compose a Response to This Article
Other responses
No responses have been published for this article.